{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T03:26:08Z","timestamp":1789961168628,"version":"4.0.1"},"reference-count":164,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The association between psoriasis and increased cancer risk is gaining recognition as studies reveal shared inflammatory and immune pathways. This review examines the relationship between psoriasis and neoplasia, focusing on cancer risk factors in psoriasis patients, the biological pathways underlying this connection, and the impact of various psoriasis treatments on cancer development. Psoriasis patients have a heightened incidence of certain cancers, such as lymphomas, skin cancers, and urological malignancies, potentially linked to immune dysregulation and chronic inflammation. Immunomodulatory treatments for psoriasis, including conventional systemic therapies and biologics, present varied cancer risks, with others, such as phototherapy, associated with an elevated risk of skin cancers. For oncologic patients with psoriasis, management necessitates a tailored approach, balancing effective psoriasis control with minimizing cancer progression risks. The emergence of IL-17 inhibitors, IL-23 inhibitors, and small-molecule therapies offers promising therapeutic alternatives with favorable safety profiles for these patients. This review underscores the need for interdisciplinary collaboration to optimize care for patients managing both psoriasis and malignancy.<\/jats:p>","DOI":"10.3390\/cancers16244224","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T11:17:22Z","timestamp":1734520642000},"page":"4224","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Intersection of Psoriasis and Neoplasia: Risk Factors, Therapeutic Approaches, and Management Strategies"],"prefix":"10.3390","volume":"16","author":[{"given":"Larisa-Alexandra","family":"Mateescu","sequence":"first","affiliation":[{"name":"2nd Department of Dermatology, Colentina Clinical Hospital, 020125 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5964-7699","authenticated-orcid":false,"given":"Alexandra-Petru\u021ba","family":"Savu","sequence":"additional","affiliation":[{"name":"2nd Department of Dermatology, Colentina Clinical Hospital, 020125 Bucharest, Romania"},{"name":"Faculty of Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costina-Cristiana","family":"Mutu","sequence":"additional","affiliation":[{"name":"2nd Department of Dermatology, Colentina Clinical Hospital, 020125 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cezara-Diana","family":"Vaida","sequence":"additional","affiliation":[{"name":"2nd Department of Dermatology, Colentina Clinical Hospital, 020125 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2600-614X","authenticated-orcid":false,"given":"Elena-Daniela","family":"\u0218erban","sequence":"additional","affiliation":[{"name":"2nd Department of Dermatology, Colentina Clinical Hospital, 020125 Bucharest, Romania"},{"name":"Faculty of Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0218tefana","family":"Bucur","sequence":"additional","affiliation":[{"name":"2nd Department of Dermatology, Colentina Clinical Hospital, 020125 Bucharest, Romania"},{"name":"Faculty of Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6414-0841","authenticated-orcid":false,"given":"Elena","family":"Poenaru","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4828-464X","authenticated-orcid":false,"given":"Alin-Codru\u021b","family":"Nicolescu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"EgoClinic, District 1, 010235 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Magdalena","family":"Constantin","sequence":"additional","affiliation":[{"name":"2nd Department of Dermatology, Colentina Clinical Hospital, 020125 Bucharest, Romania"},{"name":"Faculty of Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/annrheumdis-2018-214065","article-title":"Prevalence and incidence of psoriasis and psoriatic arthritis","volume":"78","author":"Sewerin","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: A systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jaad.2008.01.006","article-title":"National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening","volume":"58","author":"Kimball","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3892\/etm.2021.10413","article-title":"Psoriasis beyond the skin: Ophthalmological changes (Review)","volume":"22","author":"Constantin","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamadermatol.2020.0024","article-title":"Prevalence, Incidence, and Risk of Cancer in Patients with Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-analysis","volume":"156","author":"Vaengebjerg","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1038\/jid.2009.113","article-title":"Psoriasis and risk of incident cancer: An inception cohort study with a nested case-control analysis","volume":"129","author":"Brauchli","year":"2009","journal-title":"J. Investig. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamadermatol.2019.3056","article-title":"Association of Psoriasis with the Risk of Developing or Dying of Cancer: A Systematic Review and Meta-analysis","volume":"155","author":"Trafford","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/jdv.12165","article-title":"Risk of cancer in psoriasis: A systematic review and meta-analysis of epidemiological studies","volume":"27","author":"Pouplard","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.semarthrit.2020.12.008","article-title":"Malignancy in psoriatic disease: Results from prospective longitudinal cohorts","volume":"51","author":"Polachek","year":"2021","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1007\/s12325-024-02968-w","article-title":"The Impact of Psoriasis Treatments on the Risk of Skin Cancer: A Narrative Review","volume":"41","author":"Potestio","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/jdv.13619","article-title":"Skin cancer in patients with psoriasis","volume":"30","author":"Egeberg","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jaad.2016.05.021","article-title":"Personal history of psoriasis and risk of nonmelanoma skin cancer (NMSC) among women in the United States: A population-based cohort study","volume":"75","author":"Dai","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jaad.2010.04.046","article-title":"The risk of cancer in patients with psoriasis: A population-based cohort study in Taiwan","volume":"65","author":"Chen","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1523-1747.2000.00898.x","article-title":"Psoriasis, its treatment, and cancer in a cohort of Finnish patients","volume":"114","author":"Pukkala","year":"2000","journal-title":"J. Investig. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.1365-2133.1999.02655.x","article-title":"Malignant tumours and psoriasis: A follow-up study","volume":"140","author":"Frentz","year":"1999","journal-title":"Br. J. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1684\/ejd.2014.2501","article-title":"Reduced frequency of melanoma in 72,739 patients with psoriasis: A retrospective study","volume":"25","author":"Paradisi","year":"2015","journal-title":"Eur. J. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1038\/sj.jid.5700410","article-title":"The risk of lymphoma in patients with psoriasis","volume":"126","author":"Gelfand","year":"2006","journal-title":"J. Investig. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1046\/j.0022-202x.2001.01520.x","article-title":"Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden","volume":"117","author":"Boffetta","year":"2001","journal-title":"J. Investig. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0959-8049(02)00773-6","article-title":"Viral infection, atopy and mycosis fungoides: A European multicentre case-control study","volume":"39","author":"Morales","year":"2003","journal-title":"Eur. J. Cancer."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1023\/B:CACO.0000027506.55846.5d","article-title":"Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women","volume":"15","author":"Zhang","year":"2004","journal-title":"Cancer Causes Control."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/sj.bjc.6605027","article-title":"Cancer risk in hospitalised psoriasis patients: A follow-up study in Sweden","volume":"100","author":"Ji","year":"2009","journal-title":"Br. J. Cancer."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40257-017-0337-2","article-title":"Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update","volume":"19","author":"Geller","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/jamadermatol.2015.4847","article-title":"The Risk of Cancer in Patients with Psoriasis: A Population-Based Cohort Study in the Health Improvement Network","volume":"152","author":"Shin","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s10552-011-9773-0","article-title":"Association between psoriasis and incident cancer: The Iowa\u2019s Women\u2019s Health Study","volume":"22","author":"Prizment","year":"2011","journal-title":"Cancer Causes Control."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdermsci.2011.03.002","article-title":"Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan","volume":"63","author":"Tsai","year":"2011","journal-title":"J. Dermatol. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/art.23185","article-title":"Prevalence of malignancy in psoriatic arthritis","volume":"58","author":"Rohekar","year":"2008","journal-title":"Arthritis Rheum."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"490","DOI":"10.4049\/jimmunol.1100123","article-title":"Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis","volume":"187","author":"Lin","year":"2011","journal-title":"J. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/0092-8674(90)90186-I","article-title":"A genetic model for colorectal tumorigenesis","volume":"61","author":"Fearon","year":"1990","journal-title":"Cell"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/carcin\/bgp127","article-title":"Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability","volume":"30","author":"Colotta","year":"2009","journal-title":"Carcinogenesis"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10555-006-9016-0","article-title":"Inflammation and disease progression","volume":"25","author":"Krishnamoorthy","year":"2006","journal-title":"Cancer Metastasis Rev."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Denaro, N., Nazzaro, G., Murgia, G., Scarf\u00ec, F., Cauchi, C., Carrera, C.G., Cattaneo, A., Solinas, C., Scartozzi, M., and Marzano, A.V. (2023). A Multidisciplinary Approach to Patients with Psoriasis and a History of Malignancies or On-Treatment for Solid Tumors: A Narrative Literature Review. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242417540"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/path.2287","article-title":"TNF-mediated inflammatory disease","volume":"214","author":"Bradley","year":"2008","journal-title":"J. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Jang, D.-i., Lee, A.-H., Shin, H.-Y., Song, H.-R., Park, J.-H., Kang, T.-B., Lee, S.-R., and Yang, S.-H. (2021). The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052719"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1158\/1541-7786.MCR-05-0261","article-title":"Inflammation, a key event in cancer development","volume":"4","author":"Lu","year":"2006","journal-title":"Mol. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1634\/theoncologist.11-4-397","article-title":"TNF-alpha in cancer treatment: Molecular insights, antitumor effects, and clinical utility","volume":"11","author":"Eggermont","year":"2006","journal-title":"Oncologist"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e20190297","DOI":"10.1084\/jem.20190297","article-title":"The role of interleukin-17 in tumor development and progression","volume":"217","author":"Zhao","year":"2020","journal-title":"J. Exp. Med."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"He, D., Li, H., Yusuf, N., Elmets, C.A., Athar, M., Katiyar, S.K., and Xu, H. (2012). IL-17 mediated inflammation promotes tumor growth and progression in the skin. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0032126"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jdin.2024.06.006","article-title":"The role of interleukin-17 and interleukin-23 inhibitors in the development, progression, and recurrence of cancer: A systematic review","volume":"17","author":"Vangilbergen","year":"2024","journal-title":"JAAD Int."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e20190456","DOI":"10.1084\/jem.20190456","article-title":"Targeting the interleukin-17 immune axis for cancer immunotherapy","volume":"217","author":"Vitiello","year":"2020","journal-title":"J. Exp. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"623759","DOI":"10.1155\/2014\/623759","article-title":"The role of interleukin 17 in tumour proliferation, angiogenesis, and metastasis","volume":"2014","author":"Yang","year":"2014","journal-title":"Mediators Inflamm."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.it.2013.07.004","article-title":"A balance of interleukin-12 and -23 in cancer","volume":"34","author":"Ngiow","year":"2013","journal-title":"Trends Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cytogfr.2021.12.002","article-title":"Participation of interferons in psoriatic inflammation","volume":"64","author":"Gu","year":"2022","journal-title":"Cytokine Growth Factor. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"100066","DOI":"10.1016\/j.xjidi.2021.100066","article-title":"Identification of Keratinocyte Mitogens: Implications for Hyperproliferation in Psoriasis and Atopic Dermatitis","volume":"2","author":"Niehues","year":"2021","journal-title":"JID Innov."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Wu, X., Ma, Y., Wang, L., and Qin, X. (2023). A Route for Investigating Psoriasis: From the Perspective of the Pathological Mechanisms and Therapeutic Strategies of Cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241814390"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1158\/0008-5472.CAN-22-0657","article-title":"Early Insights into cancer epigenetics: Gene promoter hypermethylation emerges as a potential biomarker for cancer detection","volume":"82","author":"Clark","year":"2022","journal-title":"Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.trecan.2022.06.005","article-title":"Single cell cancer epigenetics","volume":"8","author":"Esteller","year":"2022","journal-title":"Trends Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.jaci.2019.10.015","article-title":"Epigenetic factors involved in the pathophysiology of inflammatory skin diseases","volume":"145","author":"Mobus","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaut.2016.12.002","article-title":"Epigenetics of psoriatic disease: A systematic review and critical appraisal","volume":"78","author":"Pollock","year":"2017","journal-title":"J. Autoimmun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.semcdb.2021.06.018","article-title":"Keratin 17 in psoriasis: Current understanding and future perspectives","volume":"128","author":"Lin","year":"2021","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/ng.665","article-title":"Keratin 17 promotes epithelial proliferation and tumor growth by polarizing the immune response in skin","volume":"42","author":"Depianto","year":"2010","journal-title":"Nat. Genet."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/path.5178","article-title":"Keratin 17 in disease pathogenesis: From cancer to dermatoses","volume":"247","author":"Yang","year":"2019","journal-title":"J. Pathol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1158\/0008-5472.CAN-21-2522","article-title":"Dissecting the oncogenic roles of keratin 17 in the hallmarks of cancer","volume":"82","author":"Baraks","year":"2021","journal-title":"Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.autrev.2015.05.004","article-title":"Emerging role of long noncoding RNAs in autoimmune diseases","volume":"14","author":"Wu","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.gpb.2015.09.006","article-title":"Roles, functions, and mechanisms of long non-coding RNAs in cancer","volume":"14","author":"Fang","year":"2016","journal-title":"Genom. Proteom. Bioinform."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/1744666X.2020.1754194","article-title":"Cancer risk in patients with psoriasis: Should we be paying more attention?","volume":"16","author":"Loft","year":"2020","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Constantin, M.M., Bucur, S., Mutu, C.C., Poenaru, E., Olteanu, R., Ionescu, R.A., Nicolescu, A.C., Furtunescu, F., and Constantin, T. (2021). The Impact of Smoking on Psoriasis Patients with Biological Therapies in a Bucharest Hospital. J. Pers. Med., 11.","DOI":"10.3390\/jpm11080752"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA A Cancer J. Clin."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1365-2133.2011.10526.x","article-title":"Smoking and pathogenesis of psoriasis: A review of oxidative, inflammatory and genetic mechanisms","volume":"165","author":"Armstrong","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Butr\u00f3n-Bris, B., Daud\u00e9n, E., and Rodr\u00edguez-Jim\u00e9nez, P. (2021). Psoriasis Therapy and Skin Cancer: A Review. Life, 11.","DOI":"10.3390\/life11101109"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1600-0625.2009.01034.x","article-title":"Topical hydrocortisone, clobetasol propionate, and calcipotriol do not increase photocarcinogenesis induced by simulated solar irradiation in hairless mice","volume":"19","author":"Lerche","year":"2010","journal-title":"Exp. Dermatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jphotobiol.2004.09.010","article-title":"1,25-Dihydroxyvitamin D3 and analogues protect primary human keratinocytes against UVB-induced DNA damage","volume":"78","author":"Garmyn","year":"2005","journal-title":"J. Photochem. Photobiol. B"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.11124\/JBISRIR-2017-003393","article-title":"Long-term topical corticosteroid use and risk of skin cancer: A systematic review","volume":"16","author":"Ratib","year":"2018","journal-title":"JBI Database Syst. Rev. Implement. Rep."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1517\/17425250902721250","article-title":"Efficacy and safety of topical tazarotene: A review","volume":"5","author":"Talpur","year":"2009","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/09546630701496347","article-title":"Coal tar in dermatology","volume":"18","author":"Roelofzen","year":"2007","journal-title":"J. Dermatolog Treat."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2133.1985.tb02048.x","article-title":"Further evidence of the safety of tar in the management of psoriasis","volume":"113","author":"Jones","year":"1985","journal-title":"Br. J. Dermatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/sj.bjc.6604796","article-title":"Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin\u2019s lymphoma: A population-based case-control study","volume":"100","author":"Jensen","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2310\/7750.2012.11124","article-title":"Phototherapy in psoriasis: A review of mechanisms of action","volume":"17","author":"Wong","year":"2013","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_72","first-page":"55","article-title":"Phototherapy and DNA Damage: A Systematic Review","volume":"16","author":"Oulee","year":"2023","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jaad.2011.04.004","article-title":"The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: A 30-year prospective study","volume":"66","author":"Stern","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1056\/NEJM199704103361501","article-title":"Malignant Melanoma in Patients Treated for Psoriasis with Methoxsalen (Psoralen) and Ultraviolet A Radiation (PUVA)","volume":"336","author":"Stern","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/1523-1747.ep12292698","article-title":"Noncutaneous malignant tumors in the PUVA follow-up study: 1975\u20131996","volume":"108","author":"Stern","year":"1997","journal-title":"J. Invest. Dermatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jaad.2008.12.031","article-title":"Treatments for psoriasis and the risk of malignancy","volume":"60","author":"Patel","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1365-2133.2008.08776.x","article-title":"Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy","volume":"159","author":"Hearn","year":"2008","journal-title":"Br. J. Dermatol"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-4632.2004.02186.x","article-title":"UVB phototherapy and skin cancer risk: A review of the literature","volume":"44","author":"Lee","year":"2005","journal-title":"Int. J. Dermatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2009.03389.x","article-title":"European S3-guidelines on the systemic treatment of psoriasis vulgaris","volume":"23","author":"Pathirana","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"West, J., Ogston, S., and Foerster, J. (2016). Safety and efficacy of methotrexate in psoriasis: A meta-analysis of published trials. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0153740"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Hong, J.Y., Ahn, J., Won, S., Kim, S.M., Cho, Y.A., Kim, C.Y., Sung, J.Y., Yu, D.A., Lee, Y.W., and Choe, Y.B. (2022). Risk of malignancy in patients with psoriasis according to treatment modalities in Korea: A nationwide cohort study. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-23518-w"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semcancer.2013.12.001","article-title":"Lymphoma development in patients with autoimmune and inflammatory disorders\u2013what are the driving forces?","volume":"24","author":"Baecklund","year":"2014","journal-title":"Semin. Cancer Biol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/art.20311","article-title":"Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40744-017-0064-4","article-title":"Malignancy incidence, management, and prevention in patients with rheumatoid arthritis","volume":"4","author":"Wilton","year":"2017","journal-title":"Rheu matol. Ther."},{"key":"ref_85","first-page":"1059","article-title":"Non-Melanoma Skin Cancer Risk Among Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"18","author":"DeShazo","year":"2019","journal-title":"J. Drugs Dermatol."},{"key":"ref_86","first-page":"164","article-title":"Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer","volume":"152","author":"Scott","year":"2016","journal-title":"JAMA"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.clindermatol.2009.03.003","article-title":"Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: Facts and controversies","volume":"28","author":"Naldi","year":"2010","journal-title":"Clin. Dermatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/rheumatology\/kew214","article-title":"Disease-modifying anti-rheumatic drugs and non-melanoma skin cancer in inflammatory arthritis patients: A retrospective cohort study","volume":"55","author":"Lange","year":"2016","journal-title":"Rheumatology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1111\/bjd.15170","article-title":"Methotrexate treatment and risk for cutaneous malignant melanoma: A retrospective comparative registry-based cohort study","volume":"176","author":"Polesie","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/art.23716","article-title":"Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate","volume":"59","author":"Buchbinder","year":"2008","journal-title":"Arthritis Care Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjd.18887","article-title":"Methotrexate treatment for patients with psoriasis and risk of cutaneous melanoma: A nested case\u2013control study","volume":"183","author":"Polesie","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1378\/chest.123.6.2150","article-title":"Methotrex ate-induced pulmonary lymphoma","volume":"123","author":"Ebeo","year":"2003","journal-title":"Chest"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/archderm.1997.03890430083011","article-title":"Epstein-Barr virus-associated lymphoprolifer ative disorders during methotrexate therapy for psoriasis","volume":"133","author":"Paul","year":"1997","journal-title":"Arch. Dermatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"379","DOI":"10.4103\/0378-6323.42919","article-title":"Hodgkin\u2019s lymphoma in a patient of psoriasis treated with long-term, low-dose methotrexate therapy","volume":"74","author":"Khopkar","year":"2008","journal-title":"Indian. J. Dermatol. Venereol. Leprol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1440-1843.2007.01139.x","article-title":"Pulmonary lymphoma developed during long-term methotrexate therapy for psoriasis","volume":"12","author":"Suzuki","year":"2007","journal-title":"Respirology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"369","DOI":"10.7326\/M19-3369","article-title":"Adverse Effects of Low-Dose Methotrexate: A Randomized Trial","volume":"172","author":"Solomon","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.semarthrit.2013.08.003","article-title":"Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs","volume":"43","author":"Solomon","year":"2014","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1529-8019.2007.00137.x","article-title":"Systemic ciclosporin and tacrolimus in dermatology","volume":"20","author":"Madan","year":"2007","journal-title":"Dermatol. Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJM197909063011015","article-title":"Cyclosporine A for psoriasis","volume":"301","author":"Mueller","year":"1979","journal-title":"N. Engl. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/17401","article-title":"Cyclosporine induces cancer progression by a cell-autonomous mechanism","volume":"397","author":"Hojo","year":"1999","journal-title":"Nature"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1523-1747.2003.12040.x","article-title":"Risk of malignancies in psoriasis patients treated with cyclosporine: A 5 y cohort study","volume":"120","author":"Paul","year":"2003","journal-title":"J. Investig. Dermatol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S0140-6736(01)06179-7","article-title":"Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: Nested cohort crossover study","volume":"358","author":"Marcil","year":"2001","journal-title":"Lancet"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2340\/00015555-0360","article-title":"Long-term follow-up of cancer risk in patients treated with short-term cyclosporine","volume":"88","author":"Reitamo","year":"2008","journal-title":"Acta Derm. Venereol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3109\/03009749209101481","article-title":"Safety aspects of the long-term cyclosporine A therapy","volume":"21","author":"Kurki","year":"1992","journal-title":"Scand. J. Rheumatol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0896-8411(89)80010-1","article-title":"The risk of neoplasms in patients treated with cyclosporine A","volume":"2","author":"Cockburn","year":"1989","journal-title":"J. Autoimmun."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/0190-9622(92)70117-X","article-title":"The devel opment of B-cell lymphoma in a patient with psoriasis treated with cyclosporine","volume":"26","author":"Koo","year":"1992","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"759","DOI":"10.4103\/0378-6323.120721","article-title":"Acitretin in dermatology","volume":"79","author":"Sarkar","year":"2013","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/j.1365-2133.2010.09755.x","article-title":"British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology","volume":"162","author":"Ormerod","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1097\/DSS.0000000000002072","article-title":"Use of topical and systemic retinoids in solid organ transplant recipients: Update and review of the current literature","volume":"45","author":"Herold","year":"2019","journal-title":"Dermatol. Surg."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00403-015-1593-8","article-title":"Drug safety of systemic treatments for psoriasis: Results from The German Psoriasis Registry PsoBest","volume":"307","author":"Reich","year":"2015","journal-title":"Arch. Dermatol. Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1111\/jdv.15019","article-title":"Long-term real-life safety profile and effectiveness of fumaric acid esters in psoriasis patients: Asingle-centre, retrospective, observational study","volume":"32","author":"Dickel","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_112","first-page":"223","article-title":"Malignant melanoma during treatment with fumaric acid esters\u2013coincidence or treatment-related?","volume":"9","author":"Barth","year":"2011","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Tsai, C.J., Lin, Y.C., Chen, C.Y., Hung, C.H., and Lin, Y.C. (2023). The Effects of Biologics on Hematologic Malignancy Development in Patients with Ankylosing Spondylitis, Psoriasis, or Psoriatic Arthritis: A National Cohort Study. Biomedicines, 11.","DOI":"10.3390\/biomedicines11092510"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s40261-023-01306-2","article-title":"Safety of Interleukin Inhibitors in Patients with Plaque Psoriasis and Neoplasm: A Retrospective Study from Two Referral Centers","volume":"43","author":"Gargiulo","year":"2023","journal-title":"Clin. Drug Investig."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/bjd.16715","article-title":"Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: A meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland","volume":"179","author":"Descalzo","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1038\/onc.2008.275","article-title":"Cytokine-based transformation of immune surveillance into tumor-promoting inflammation","volume":"27","author":"Mumm","year":"2008","journal-title":"Oncogene"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/bjd.15830","article-title":"Risk of cancer in patients with psoriasis on biological therapies: A systematic review","volume":"178","author":"Peleva","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jaad.2010.09.734","article-title":"The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: A systematic review and meta-analysis of randomized controlled trials","volume":"64","author":"Dommasch","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/jdv.12675","article-title":"An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors","volume":"29","author":"Menting","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jaad.2004.07.031","article-title":"Rapid onset of cutaneous squamous cell carcinoma of the penis in a patient with psoriasis on etanercept therapy","volume":"51","author":"Fryrear","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/j.1365-2133.2007.08182.x","article-title":"The rapid onset of multiple squamous cell carcinomas during etanercept treatment for psoriasis","volume":"157","author":"Ly","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"ref_122","first-page":"282","article-title":"Non-Melanoma Skin Cancer Risk Among Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"152","author":"Fuxench","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/annrheumdis-2016-209285","article-title":"Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: Results from a collaborative project of 11 European biologic registers","volume":"76","author":"Mercer","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jaad.2016.10.006","article-title":"Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population","volume":"76","author":"Asgari","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"f1939","DOI":"10.1136\/bmj.f1939","article-title":"Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: Nationwide population based prospective cohort study from Sweden","volume":"346","author":"Raaschou","year":"2013","journal-title":"BMJ"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/CMR.0000000000000284","article-title":"Melanoma risk in patients with rheumatoid arthritis treated with tumour necrosis factor alpha inhibitors: A systematic review and meta-analysis","volume":"26","author":"Olsen","year":"2016","journal-title":"Melanoma Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjd.17084","article-title":"Compre hensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis","volume":"180","author":"Leonardi","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1136\/ard.2009.117762","article-title":"Lymphoma in patients treated with anti-TNF: Results of the 3-year prospective French RATIO registry","volume":"69","author":"Mariette","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s13555-023-01074-z","article-title":"Risk of Cutaneous T Cell Lymphoma with Psoriasis Biologic Therapies","volume":"14","author":"Davis","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2133.2008.08664.x","article-title":"Gastric MALT lymphoma in a patient receiving infliximab for psoriasis","volume":"159","author":"Girard","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/ajh.20926","article-title":"TNF-a inhibitor etanercept and hematologic malignancies: Report of a case and review of the literature","volume":"82","author":"Nair","year":"2007","journal-title":"Am. J. Hematol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/cncr.22944","article-title":"A placebo-controlled double blind trial of etanercept for the cancer anorexia\/weight loss syndrome: Results from N00C1 from the North Central Cancer Treatment Group","volume":"110","author":"Jatoi","year":"2007","journal-title":"Cancer"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Yan, J., Smyth, M.J., and Teng, M.W.L. (2018). Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer. Cold Spring Harb. Perspect. Biol., 10.","DOI":"10.1101\/cshperspect.a028530"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"17093","DOI":"10.1007\/s00432-023-05387-6","article-title":"Cancer risks in patients with psoriasis administered biologics therapy: A nationwide population-based study","volume":"149","author":"Jung","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.12214","article-title":"Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: Final results from 5 years of follow-up","volume":"168","author":"Papp","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jaad.2011.06.041","article-title":"Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials","volume":"66","author":"Gordon","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/jdv.19520","article-title":"Are interleukin 17 and interleukin 23 inhibitors associated with malignancies?\u2014Insights from an international population-based study","volume":"38","author":"Kridin","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/978-3-030-55617-4_6","article-title":"IL-23 and the Tumor Microenvironment","volume":"1290","author":"Subhadarshani","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_139","first-page":"1","article-title":"The use of interleukin-23 inhibitors to treat immune-related psoriasis induced by immune checkpoint inhibitors and in patients with active cancer: A case series and review of the literature","volume":"11","author":"Fournier","year":"2023","journal-title":"SAGE Open Med. Case Rep."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1080\/14712598.2022.2152322","article-title":"Biologic treatment of psoriasis in oncologic patients","volume":"22","author":"Puig","year":"2022","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Battista, T., Gallo, L., Martora, F., Fattore, D., Potestio, L., Cacciapuoti, S., Scalvenzi, M., and Megna, M. (2024). Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study. J. Clin. Med., 13.","DOI":"10.3390\/jcm13071940"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e14889","DOI":"10.1111\/dth.14889","article-title":"IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: A case series with systematic literature review","volume":"34","author":"Bellinato","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","article-title":"Apremilast mechanism of action and application to psoriasis and psoriatic arthritis","volume":"83","author":"Schafer","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"e2022179","DOI":"10.5826\/dpc.1204a179","article-title":"Apremilast in Psoriasis Patients with Serious Comorbidities: A Case Series and Systematic Review of Literature","volume":"12","author":"Tsentemeidou","year":"2022","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"645","DOI":"10.36849\/JDD.8293","article-title":"Selective Tyrosine Kinase 2 (TYK2) Inhibition in Plaque Psoriasis","volume":"23","author":"Kircik","year":"2024","journal-title":"J. Drugs Dermatol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1177\/10600280231153863","article-title":"Deucravacitinib: The First FDA-Approved Oral TYK2 Inhibitor for Moderate to Severe Plaque Psoriasis","volume":"58","author":"Truong","year":"2024","journal-title":"Ann. Pharmacother."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special Article: 2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jaad.2020.02.044","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies","volume":"82","author":"Menter","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Results from two randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1080\/1744666X.2018.1512404","article-title":"Tofacitinib for the treatment of psoriasis and psoriatic arthritis","volume":"14","author":"Berekmeri","year":"2018","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s40264-020-00904-9","article-title":"An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data","volume":"43","author":"Burmester","year":"2020","journal-title":"Drug Saf."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1080\/14656566.2016.1195812","article-title":"Tofacitinib for the treatment of psoriasis","volume":"17","author":"Galluzzo","year":"2016","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Fonseca, D., Nogueira, M., and Torres, T. (2023). Upadacitinib for the treatment of psoriatic arthritis. Drugs Context., 12.","DOI":"10.7573\/dic.2022-11-6"},{"key":"ref_156","unstructured":"European Medicines Agency (2024, October 01). Upadacitinib Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rinvoq-epar-product-information_en.pdf."},{"key":"ref_157","unstructured":"US Food and Drug Administration (2024, October 01). Upadacitinib Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211675s000lbl.pdf."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/jdv.16926","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris\u2013Part 2: Specific clinical and comorbid situations","volume":"35","author":"Nast","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/cdd.2013.67","article-title":"Immune-based mechanisms of cytotoxic chemotherapy: Implications for the design of novel and rationale-based combined treatments against cancer","volume":"21","author":"Bracci","year":"2014","journal-title":"Cell Death Differ."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Lee, H.-J., and Kim, M. (2023). Challenges and Future Trends in the Treatment of Psoriasis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241713313"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.currproblcancer.2017.10.003","article-title":"Anti-PD1\/PDL1 induced psoriasis","volume":"41","author":"Voudouri","year":"2017","journal-title":"Curr. Probl. Cancer"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s13555-023-00905-3","article-title":"Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel","volume":"13","author":"Papp","year":"2023","journal-title":"Dermatol. Ther."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/24\/4224\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:55:02Z","timestamp":1760115302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/24\/4224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":164,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["cancers16244224"],"URL":"https:\/\/doi.org\/10.3390\/cancers16244224","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]}}}